HTF Market Intelligence released a new research report of 147 pages on title ‘Candidiasis – Pipeline Review, H1 2017’ with detailed analysis, forecast and strategies.
Latest Pharmaceutical and Healthcare disease pipeline guide Candidiasis – Pipeline Review, H1 2017, provides an overview of the Candidiasis (Infectious Disease) pipeline landscape.
Candidiasis is caused by infection with species of the genus Candida, predominantly with Candida albicans. A Candida infection of the skin appears as a clearly defined patch of red, itchy skin, often leaking fluid. Scabs and pustules may be seen around the edge of the rash. It will usually be found in areas such as the groin, the folds of the buttocks, between the breasts, toes, or fingers, and in the navel. Treatment includes anti fungal drugs.
Request a sample report @ https://www.htfmarketreport.com/sample-report/304208-candidiasis-pipeline-review
Pharmaceutical and Healthcare latest pipeline guide Candidiasis – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Candidiasis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Candidiasis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Candidiasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 8, 4, 20 and 10 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 10 and 9 molecules, respectively.
Candidiasis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Markets proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
– The pipeline guide provides a snapshot of the global therapeutic landscape of Candidiasis (Infectious Disease).
– The pipeline guide reviews pipeline therapeutics for Candidiasis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Candidiasis (Infectious Disease) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Candidiasis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Candidiasis (Infectious Disease)
Buy this report @ https://www.htfmarketreport.com/buy-now?format=1&report=304208
Companies Mentioned in the Report
Amplyx Pharmaceuticals Inc
Bakker Medical Srl
Biomar Microbial Technologies
Cidara Therapeutics Inc
CSA Biotechnologies LLC
Daewoong Pharmaceutical Co Ltd
General Biologicals Corp
Grupo Ferrer Internacional SA
Hsiri Therapeutics LLC
iCo Therapeutics Inc.
Matinas BioPharma Holdings Inc
NovaDigm Therapeutics Inc
Sealife PHARMA GMBH
Viamet Pharmaceuticals Inc
Wellstat Vaccines LLz
View Detailed Table of Content @ https://www.htfmarketreport.com/reports/304208-candidiasis-pipeline-review
Table of Contents
List of Tables 5
List of Figures 6
Global Markets Direct Report Coverage 7
Candidiasis – Overview 8
Candidiasis – Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Pipeline by Universities/Institutes 13
Products under Development by Companies 15
Products under Development by Universities/Institutes 18
Candidiasis – Therapeutics Assessment 19
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Candidiasis – Companies Involved in Therapeutics Development 27
Amplyx Pharmaceuticals Inc 27
Bakker Medical Srl 27
Biomar Microbial Technologies 28
Biosergen AS 28
Cidara Therapeutics Inc 29
CSA Biotechnologies LLC 29
Daewoong Pharmaceutical Co Ltd 30
Dermala Inc 30
General Biologicals Corp 31
Grupo Ferrer Internacional SA 31
Featured News & Press Releases 130
Secondary Research 141
Primary Research 141
Expert Panel Validation 141
Contact Us 141
Disclaimer 142 List of Tables
Number of Products under Development for Candidiasis, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Candidiasis – Pipeline by Amplyx Pharmaceuticals Inc, H1 2017
Candidiasis – Pipeline by Bakker Medical Srl, H1 2017
Candidiasis – Pipeline by Biomar Microbial Technologies, H1 2017
Candidiasis – Pipeline by Biosergen AS, H1 2017
Candidiasis – Pipeline by Cidara Therapeutics Inc, H1 2017
Candidiasis – Pipeline by CSA Biotechnologies LLC, H1 2017
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Candidiasis (Infectious Disease).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Candidiasis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Make an enquiry before buying this Report @ https://www.htfmarketreport.com/enquiry-before-buy/304208-candidiasis-pipeline-review
CRAIG FRANCIS (PR & Marketing Manager)
Ph: +1 (206) 317 1218